Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXD5QP)

Drug Name

SAR442257 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Malignant neoplasm	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclic ADP-ribose hydrolase 1 (CD38)	TTPURFN	CD38_HUMAN	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Cyclic ADP-ribose hydrolase 1 (CD38)	DTT	CD38	6.658	6.115	5.04	6.932

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Malignant neoplasm

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cyclic ADP-ribose hydrolase 1 (CD38)	DTT	CD38	8.33E-02	0.22	0.69

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04401020) First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Sanofi.